326921-25-9
326921-25-9
Chemical Structure
TKIM
- CAS No.: 326921-25-9
- Formula:C18H14ClN3O2S
- Molecular Weight:371.84
IUPAC Name: 4-chloro-N'-(2-(quinolin-2-ylthio)acetyl)benzohydrazide
InChIKey: BWTKIGGLLXUFSV-UHFFFAOYSA-N
SMILES: O=C(NNC(CSC1=NC2=CC=CC=C2C=C1)=O)C3=CC=C(Cl)C=C3
Biological Activity: TKIM is a TREK-1 channel inhibitor with an IC50 of 2.96 μM. TKIM binds to the pocket of the intermediate (IM) state of TREK-1[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TKIM | 99.73% | TKIM is a TREK-1 channel inhibitor with an IC50 of 2.96 μM. TKIM binds to the pocket of the intermediate (IM) state of TREK-1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VEGFR-IN-1 | 99.07% | VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Halofenozide | 99.27% | Halofenozide (RH-0345) is an ecdysteroid agonist. RH-0345 belongs to a new group of insect growth regulators (IGRs) with a benzoylhydrazine structure that mimic the action of the natural insect molting hormone 20-hydroxyecdysone. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MPT0G211 | 99.79% | MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TCN 201 | 98.08% | TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC50 of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC50<4.3). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC-IN-27 | 98.12% | HDAC-IN-27 (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC50 values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 can be used for research in acute myeloid leukemia (AML). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC-IN-27 dihydrochloride | 99.08% | HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC50 values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 dihydrochloride exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 dihydrochloride demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 dihydrochloride can be used for research in acute myeloid leukemia (AML). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
dCeMM3 | 98.19% | dCeMM3 (Compound 3) is a molecular glue degrader. dCeMM3 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Elastase-IN-1 | Elastase-IN-1 (Compound Q11) is an elastase inhibitor with an IC50 of 0.897 µM. Elastase-IN-1 is non-toxic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SLU-PP-332 | 98.98% | SLU-PP-332 is a pan-Estrogen Receptor/ERR agonist with EC50 values of 98, 230 and 430 nM for ERRα, ERRβ and ERRγ, respectively. SLUPP-332 enhances mitochondrial function and cellular respiration in skeletal muscle cell lines. SLU-PP-332 has the potential to study metabolic diseases as well as improve muscle function. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC3-IN-8 | HDAC3-IN-8 is a selective inhibitor targeting HDAC1, HDAC2 and HDAC3, with IC50 values of 3.52 nM for HDAC1, 15.14 nM for HDAC2 and 0.38 nM for HDAC3. HDAC3-IN-8 shows high selectivity for HDAC3 and exerts its effect by inhibiting histone deacetylase activity. HDAC3-IN-8 can be used to construct HDAC3-targeted PROTAC degrader (HY-181767) and is suitable for the research of acute myeloid leukemia (AML). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
